[go: up one dir, main page]

GB202316264D0 - Gene therapy - Google Patents

Gene therapy

Info

Publication number
GB202316264D0
GB202316264D0 GBGB2316264.7A GB202316264A GB202316264D0 GB 202316264 D0 GB202316264 D0 GB 202316264D0 GB 202316264 A GB202316264 A GB 202316264A GB 202316264 D0 GB202316264 D0 GB 202316264D0
Authority
GB
United Kingdom
Prior art keywords
gene therapy
therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2316264.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ospendale San Raffaele Srl
Consiglio Nazionale delle Richerche CNR
Original Assignee
Ospendale San Raffaele Srl
Consiglio Nazionale delle Richerche CNR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospendale San Raffaele Srl, Consiglio Nazionale delle Richerche CNR filed Critical Ospendale San Raffaele Srl
Priority to GBGB2316264.7A priority Critical patent/GB202316264D0/en
Publication of GB202316264D0 publication Critical patent/GB202316264D0/en
Priority to PCT/EP2024/080152 priority patent/WO2025088077A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2316264.7A 2023-10-24 2023-10-24 Gene therapy Ceased GB202316264D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2316264.7A GB202316264D0 (en) 2023-10-24 2023-10-24 Gene therapy
PCT/EP2024/080152 WO2025088077A1 (en) 2023-10-24 2024-10-24 Gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2316264.7A GB202316264D0 (en) 2023-10-24 2023-10-24 Gene therapy

Publications (1)

Publication Number Publication Date
GB202316264D0 true GB202316264D0 (en) 2023-12-06

Family

ID=88970104

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2316264.7A Ceased GB202316264D0 (en) 2023-10-24 2023-10-24 Gene therapy

Country Status (2)

Country Link
GB (1) GB202316264D0 (en)
WO (1) WO2025088077A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
ES2739288T3 (en) 2013-09-13 2020-01-30 California Inst Of Techn Selective recovery
EP3387137B1 (en) 2015-12-11 2021-02-03 California Institute of Technology TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
EP3235516B1 (en) * 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulatable adeno-associated virus (aav) vector
EP3863605A4 (en) * 2018-10-11 2022-10-26 Decibel Therapeutics, Inc. AAV1 VECTORS AND THEIR USES FOR THE TREATMENT OF OTIC INDICATIONS

Also Published As

Publication number Publication date
WO2025088077A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
GB202003618D0 (en) Gene Therapy
GB202114972D0 (en) Gene therapy
IL309742A (en) Optimized expression cassettes for gene therapy
CA221425S (en) Therapy eye-mask
GB201905301D0 (en) Gene therapy
GB202206346D0 (en) Gene therapy
GB202010894D0 (en) Gene therapy
GB202003109D0 (en) Gene therapy
GB202002202D0 (en) Gene therapy
IL324378A (en) Gene therapy
GB202316264D0 (en) Gene therapy
GB202315668D0 (en) Gene therapy
GB202214445D0 (en) Gene therapy
GB202212092D0 (en) Gene therapy
IL306119A (en) Gene therapy for treating beta-hemoglobinopathies
IL310018A (en) Kcnv2 gene therapy
GB202114973D0 (en) Gene therapy
GB202003536D0 (en) Gene therapy
GB202003120D0 (en) Gene therapy
GB202001930D0 (en) Gene therapy
GB202506402D0 (en) Gene therapy
SG11202110844UA (en) Mixed-cell gene therapy
GB202215198D0 (en) Gene therapy treatment
GB202407038D0 (en) Novel Gene Therapy
CA3290995A1 (en) Gene therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)